Skip to content

Study · Not a test of the peptide alone · 2026

2 results

HNF1B-MODY (MODY-5): a rare form of diabetes with multisystemic features-two case reports.

Carvalho T, Lavrador M, Saraiva J, Gomes L

Frontiers in endocrinology11 Jun 2026

PMID42369057 (opens in a new tab)PMCIDPMC13293842 (opens in a new tab)DOI10.3389/fendo.2026.1841040 (opens in a new tab)PepBankPUB-42369057
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

IntroductionMaturity-Onset Diabetes of the Young (MODY) is a rare monogenic form of diabetes characterized by early onset and autosomal dominant inheritance. MODY-5, caused by HNF1B gene mutations, accounts for <5% of MODY cases and often presents with renal abnormalities and genitourinary malformations.Case presentationWe describe two patients with HNF1B-related MODY confirmed by heterozygous 17q12 microdeletions. The first case, a 29-year-old woman, presented with diabetes, hypertension, bilateral renal cysts, mild chronic kidney disease (CKD), hypomagnesemia, mild liver enzyme elevations, and a complex Müllerian anomaly requiring surgical correction. She has maintained excellent metabolic control on metformin alone, with no diabetic complications after four years of follow-up. The second case, a 40-year-old man, had a history of diabetes, neonatal left nephrectomy for cystic dysplasia, CKD stage G3bA2, persistent liver enzyme elevation, dorsal pancreatic agenesis, hypomagnesemia, hyperuricemia, mild cognitive impairment, and infertility. He initially achieved good glycemic control with a combination of insulin, metformin, liraglutide, and dapagliflozin, though control subsequently fluctuated. To date, microalbuminuria remains his only diabetes-related complication.ConclusionsThese cases underscore the broad phenotypic spectrum of MODY 5 and highlight the importance of considering HNF1B mutations in young-onset diabetes associated with renal or genitourinary anomalies. Hypomagnesemia and abnormal liver function tests are additional features that may guide suspicion. Early recognition and genetic confirmation are essential for tailored management, complication surveillance, and family screening.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a man with HNF1B-related MODY, a regimen of insulin, metformin, liraglutide, and dapagliflozin initially achieved good glycemic control, which later fluctuated.

    In plain wordsIn one man with HNF1B-MODY, insulin, metformin, liraglutide and dapagliflozin initially controlled blood sugar, which later fluctuated.

    Peptide
    Liraglutide
    Outcome
    MixedGlycemic control
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    He initially achieved good glycemic control with a combination of insulin, metformin, liraglutide, and dapagliflozin, though control subsequently fluctuated.
    2 context sentences
    Summary · context
    We describe two patients with HNF1B-related MODY confirmed by heterozygous 17q12 microdeletions.
    Summary · context
    The second case, a 40-year-old man, had a history of diabetes, neonatal left nephrectomy for cystic dysplasia, CKD stage G3bA2, persistent liver enzyme elevation, dorsal pancreatic agenesis, hypomagnesemia, hyperuricemia, mild cognitive impairment, and infertility.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneCase report or seriesOther

    In one man with HNF1B-related MODY receiving insulin, metformin, liraglutide, and dapagliflozin, microalbuminuria remained his only diabetes-related complication to date.

    In plain wordsIn one man with HNF1B-MODY on a four-drug regimen including liraglutide, microalbuminuria remained his only diabetes-related complication.

    Peptide
    Liraglutide
    Outcome
    Not applicableMicroalbuminuria
    Study

    n = 1

    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    To date, microalbuminuria remains his only diabetes-related complication.
    3 context sentences
    Summary · context
    He initially achieved good glycemic control with a combination of insulin, metformin, liraglutide, and dapagliflozin, though control subsequently fluctuated.
    Summary · context
    We describe two patients with HNF1B-related MODY confirmed by heterozygous 17q12 microdeletions.
    Summary · context
    The second case, a 40-year-old man, had a history of diabetes, neonatal left nephrectomy for cystic dysplasia, CKD stage G3bA2, persistent liver enzyme elevation, dorsal pancreatic agenesis, hypomagnesemia, hyperuricemia, mild cognitive impairment, and infertility.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.